Because of this, and evidence for cholesterol crystal-activated inflammasomes producing IL-1β, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) was instigated. The gene discussed is IL1B; the disease is Venous thrombosis.